CO HB1007

Preauthorization and utilization review for substance use disorder and behavioral health coverage must be the same as or no more restrictive than requirements for physical illness coverage.

Health benefit plans must provide a five-day supply of at least one FDA-approved opioid dependence treatment drug without prior authorization, limited to once per twelve-month period.

Carriers cannot take adverse actions or provide financial incentives/disincentives to providers based solely on patient satisfaction surveys related to pain treatment.

Prior authorization requests for medication-assisted treatment for substance use disorders are classified as urgent requests.

Medicaid must authorize reimbursement for at least one FDA-approved ready-to-use opioid overdose reversal drug without prior authorization and establish standardized utilization management timelines for medication-assisted treatment.

Pharmacies administering injectable antagonist medication for medication-assisted treatment through collaborative pharmacy practice agreements must receive enhanced dispensing fees aligned with clinical provider administration fees.